Clinical Trials Directory

Trials / Completed

CompletedNCT00776139

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions

An Open Label, Randomized, Single-Center, Single-Dose, Two-Treatment, Two-Period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fasting Condition

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Ranbaxy Laboratories Limited · Industry
Sex
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fasting condition

Detailed description

The study was conducted as an open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability of the test formulation of cetirizine hydrochloride tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) containing containing 10 mg cetirizine hydrochloride study comparing to the marketed product, Zyrtec®, containing 10 mg of cetirizine hydrochloride of Pfizer Labs (Division of Pfizer Inc.), in healthy, adult, human, subjects under fasting condition. Safety measures were performed throughout the study and included a physical examination, laboratory evaluation, and measurement of vital signs. A total of 32 subjects were randomized to receive single oral dose of cetirizine hydrochloride 10 mg tablet and 31 subjects completed both the periods of the study.

Conditions

Interventions

TypeNameDescription
DRUGCetirizine Hydrochloride 10 mg tabletBioequivalence Cetirizine Hydrochloride 10 mg tablet

Timeline

Start date
2004-10-01
Primary completion
2004-10-01
Completion
2004-12-01
First posted
2008-10-20
Last updated
2008-10-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00776139. Inclusion in this directory is not an endorsement.